Publication date: Jul 11, 2023
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Avindra Nath, MD Researchers from the National Institutes of Health (NIH) found that 100 percent of the participants in this study had fatigue and experienced cognitive difficulties. So what can we learn from this new research to help us diagnose and treat patients with disabling neurological symptoms after they had COVID-19? To discuss the findings, Dr. Charles Turck is joined by Dr. Avindra Nath, Clinical Director of the National Institute of Neurological Disorders and Stroke.
| Concepts | Keywords |
|---|---|
| Clinics | Acute |
| Host | Autonomic |
| Mri | Charles |
| Organ | Covid |
| Pandemic | Findings |
| Found | |
| Immune | |
| Individuals | |
| Long | |
| Lot | |
| Nath | |
| Neurological | |
| Symptoms | |
| Today | |
| Underlying |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Long COVID |
| disease | IDO | host |
| disease | MESH | COVID-19 |
| disease | MESH | Neurological Disorders |
| disease | MESH | Stroke |
| disease | MESH | infection |
| disease | IDO | cell |
| drug | DRUGBANK | Nonoxynol-9 |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | syndromes |
| disease | VO | organ |
| disease | MESH | abnormalities |
| disease | IDO | blood |
| disease | MESH | seizures |
| pathway | REACTOME | Immune System |
| drug | DRUGBANK | Dopamine |
| disease | IDO | intervention |
| disease | IDO | process |
| drug | DRUGBANK | Coenzyme M |
Original Article
(Visited 1 times, 1 visits today)